ISPC - iSpecimen slumps extending recent slide to over a third

After adding more than a third of value on Tuesday, micro-cap stock iSpecimen (ISPC -17.5%) has lost sharply on below-average value. More than ~2.8M company shares have traded so far, compared to the 65-day average of ~5.3M. Despite a loss of more than a third since reaching a peak late last month, the health tech firm continues to trade 50% above its June IPO price of $8 per share. Heading into the week, the short-interest positions at iSpecimen (NASDAQ:ISPC) were elevated, Seeking Alpha Catalyst Watch alerted investors last Friday. The stock with nearly a fifth of its float on loan added more than 39% on Tuesday after ~11.5M shares changed hands. Lexington, Massachusetts-based company secured $18M in gross proceeds with its IPO, and its shares rallied in November following a contract signed with the U.S. government and some private researchers to deliver human biospecimens for COVID-19 research.

For further details see:

iSpecimen slumps extending recent slide to over a third